Through disease-specific programs, HSCI channels its world-class resources — both intellectual and technological — toward some of the most prevalent, devastating diseases for which stem cell research can hold promise.
Led by Daniel G. Tenen, M.D., the goal of the HSCI Blood Program is to discover how to turn regeneration on and off. The knowledge gained in this program has implications for leukemia and lymphoma, and for human diseases across the board.
The goal of the HSCI Cardiovascular Program, led by Richard Lee, M.D., is to generate new human heart cells to replace damaged heart tissue. This has particular implications for diseases of aging, and for heart disease.
The goal of the HSCI Diabetes Program is to cure diabetes. Led by Doug Melton, PhD, the program explores how to create beta cells efficiently, and protect them from attack by the immune system. This has direct implications for Type I Diabetes and Type II Diabetes.
Researchers in the HSCI Kidney Program, led by M. Todd Valerius, Ph.D., are dedicated to finding new treatments for patients with kidney disease. Their interests are regenerative biology in general, and fibrosis in particular.
Lee Rubin, Ph.D. and Tracy Young-Pearse, Ph.D. lead the HSCI Nervous System Diseases Program. Researchers in this program investigate neurodegenerative and traumatic diseases of the brain and spinal cord. Their goal is to understand exactly which neurons degenerate and why, and how to interfere with the degenerative process to provide a therapy. Their research covers a broad range of disorders, including ALS, Alzheimer's disease, eye diseases, hearing loss, Multiple Sclerosis, and Parkinson's disease.
Led by Markus Frank, M.D. and George F. Murphy, M.D., the HSCI Skin Program aims to discover how to regenerate tissue without scarring. Their research focuses on skin repair and regeneration and has implications for various types of skin cancers.
Get the latest research news
Sign up for the monthly HSCI newsletter to get email updates about our research.